We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0A4K market cap is 0. The company's latest EPS is USD -5.9859 and P/E is -0.02.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 10.13M | 8.5M | 17.98M | 27.8M | 36.12M |
| Operating Income | -25.87M | -38.55M | -77.1M | -131.7M | -215.25M |
| Net Income | -29.82M | -41.11M | -72.44M | -132.6M | -232.49M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 30.21M | 60.45M | 377.1M | 307.5M | 214.4M |
| Total Liabilities | 26.59M | 25.37M | 39.98M | 58.1M | 118.25M |
| Total Equity | 3.61M | 35.08M | 337.12M | 249.4M | 96.16M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -29.53M | -38.31M | -71.93M | -124.82M | -125.18M |
| Investing | -61k | -2.45M | -278.06M | 82.77M | 24.16M |
| Financing | 30.38M | 61.9M | 336.11M | 23.01M | 113.82M |
| Market Cap | 0 |
| Price to Earnings Ratio | -0.02 |
| Price to Sales Ratio | 0.14 |
| Price to Cash Ratio | 0.28 |
| Price to Book Ratio | 0.05 |
| Dividend Yield | - |
| Shares Outstanding | 38.84M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Bionano Genomics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.bionanogenomics.com |
| Industry | lab analytical instruments (3826) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
